Efficacy and safety of Cortexin as additional therapy in patients with depressive disorder
Comparison in people · 2026
- What was studied
- 98 patients with depression; 48 adjunctive Cortexin and 50 antidepressant-only, 28 days
- Main finding
- Reports differences in depression, social-function and adverse-effect ratings between treatment groups.
Depression, social adaptation and adverse-effect comparisons · Add-on group favored at visit 3 · p=0.001
Reported findings and study design
98 patients with depression: antidepressant plus Cortexin 48 versus antidepressant alone 50. Cortexin 10 mg IM daily for ten days; assessments at baseline, days 14 and 28.
Population or model 98 patients with depression; 48 adjunctive Cortexin and 50 antidepressant-only, 28 days
Dose, route and schedule
Cortexin: 10 mg intramuscularly each morning for ten days, added to antidepressant treatment.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Depression, social adaptation and adverse-effect comparisons | Add-on group favored at visit 3 | p=0.001 |
| Patient-rated substantial/significant improvement | Greater in the add-on group | p=0.001 |
The abstract supplies p-values but no numerical MADRS/SASS changes or adverse-event counts.
Source for these results ↗ · Reviewed 2026-10-29
Study limitations and source details
Study limitations
- Randomization and masking are not established in the accessible abstract.
- Short adjunctive study; not evidence for self-treatment or replacing standard psychiatric care.
Source details
Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Sources checked
Citation
Schastnyy ED. Efficacy and safety of Cortexin as additional therapy in patients with depressive disorder Zh Nevrol Psikhiatr Im S S Korsakova 126(2):92-96. PMID 41782536
Study source ↗ · DOI 10.17116/jnevro202612602192 · Bibliography entry · Link to this summary